Related coverage linked through entity extraction aliases.
Jun 13, 2026
The FDA approved pivekimab sunirine-pvzy (Decnupaz) for adults with BPDCN on May 27, 2026, based on CADENZA trial data showing a 69.7% CR/CRc rate in treatment-naïve patients.
Jul 30, 2026
The FDA granted RMAT designation to Allogene’s cema-cel for first-line LBCL consolidation and Cellectis’ lasme-cel for r/r B-ALL. Both allogeneic CAR-T therapies showed promising early efficacy and safety, with cema-cel also receiving Fast Track status.
Jul 20, 2026
Kura Oncology's ziftomenib shows 96% complete response in frontline AML and $5.8M in early commercial sales; updated FIT-001 trial data for kidney cancer to be presented at 2026 summit; analysts see significant upside with an average target of $32.45.
Jul 17, 2026
Data presented at EHA show that sickle cell disease patients have high interest in gene therapy, with 71% eager to learn more, despite limited awareness and concerns about safety and cost. Early clinical data from approved CRISPR-based therapies demonstrate significant reductions in vaso-occlusive crises and hospital admissions.
